News Feed provided by:
Hepatitis Central
Hepatitis C News, Updates and Commentary.
Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...
Date: Tue, 26 Aug 2008 10:52:01 -0500
Vertex's Advanced Trial Could Change HCV Treatment
Hundreds of non-responders to interferon-ribavirin combination therapy will be enrolled in a late stage clinical trial for Vertex's telaprevir....
Date: Fri, 22 Aug 2008 13:51:14 -0500
Silymarin Improves Quality of Life During Hepatitis C Treatment
Although a large-scale study concluded long-term interferon therapy to be ineffectual for Hepatitis C management, it demonstrated improvements in quality of life for participants supplementing with silymarin....
Date: Fri, 15 Aug 2008 15:05:57 -0500
Early Hepatitis C Treatment Increases Success
Currently approved treatment for chronic Hepatitis C is about 50 percent effective. New research from Canada claims that early treatment boosts its effectiveness up to 90 percent....
Date: Tue, 12 Aug 2008 10:16:42 -0500
Popular Blood Thinner May Reduce Liver Scarring for HCV Patients
Successful animal studies have paved the way for a human trial to determine if warfarin prevents liver damage in those with Hepatitis C....
Date: Tue, 12 Aug 2008 10:12:10 -0500
R1626 Could Help Defeat Hepatitis C
Whether added to standard combination therapy or as a monotherapy, studies show that R1626 is a powerful HCV anti-viral medicine....
Date: Tue, 05 Aug 2008 11:14:17 -0500
Diabetes Prevention a Priority with Hep C
Diet and exercise are often quoted as the solution to most of our modern health problems. For reducing the risk of developing liver cancer, new research shows that these lifestyle changes are crucial to people with chronic Hepatitis C....
Date: Thu, 31 Jul 2008 15:33:46 -0500
Two Promising Ways to Quit Alcohol
In addition to cutting the risk for fatty liver disease, research presented at the Research Society on Alcoholism conference confirmed two distinct approaches that can help those battling alcoholism....
Date: Tue, 29 Jul 2008 16:07:59 -0500
Liver Donor Pool Expands For Hepatitis C Patients
Learn about the discovery made by St. Louis researchers that will expand the liver donor pool for HCV patients, and find out if Hepatitis C serology affects post-liver transplant survival rate....
Date: Tue, 29 Jul 2008 15:48:47 -0500
Natalie Cole Optimistic About Her Battle with Hepatitis C
Although currently recovering from combination therapy's side effects, the well-respected vocalist Natalie Cole may have conquered the Hepatitis C virus....
Date: Mon, 21 Jul 2008 10:06:27 -0500
Hep C and Fatty Liver Disease Linked
Pittsburgh researchers have found an enzyme known to participate in fat production is elevated in those with Hepatitis C. Further exploration of this enzyme could help physicians better predict which HCV patients are at risk of developing fatty liver disease....
Date: Wed, 09 Jul 2008 15:29:15 -0500
Anadys' ANA773 Hepatitis C Phase I Trials in Netherlands
Reducing the dosing schedule in half, Anadys Pharmaceuticals continues its investigation of ANA773, a Toll-Like Receptor-7 agonist prodrug. Approaching the Hepatitis C virus differently from most other contenders, Phase I clinical trials evaluating the safety, tolerability and viral-load decline associated...
Date: Wed, 09 Jul 2008 15:23:07 -0500
Popular Illegal Drug Extra Harmful with HCV
Scientists have found a popular street drug worsens Hepatitis C infection in two worrisome ways....
Date: Mon, 07 Jul 2008 12:19:00 -0500
Hep C Long-Term Management Strategies
Since only about half of those on combination therapy beat Hepatitis C, the remaining people must strive to prevent their liver disease from progressing. Thus far, a liver wellness approach is a safer, more effective way to remain healthy compared...
Date: Mon, 07 Jul 2008 12:00:19 -0500
Good News for Non-Responders to HCV Combination Therapy
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead...
Date: Fri, 27 Jun 2008 10:35:43 -0500
Copyright 2008
|
Number Online:
Guests: 5
Members: 0
Total: 5
Online Now: